| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 276.23▲ | 276.50▼ | 276.62▼ | 270.54▲ | 264.94▲ |
| MA10 | 276.30▲ | 276.51▼ | 274.91▲ | 266.66▲ | 259.71▲ |
| MA20 | 276.32▲ | 274.23▲ | 272.87▲ | 265.31▲ | 250.68▲ |
| MA50 | 276.66▼ | 271.42▲ | 267.09▲ | 258.89▲ | 231.87▲ |
| MA100 | 275.02▲ | 266.76▲ | 265.92▲ | 248.11▲ | 213.24▲ |
| MA200 | 272.54▲ | 265.81▲ | 262.34▲ | 232.65▲ | 187.57▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.013▼ | 0.022▲ | 0.308▲ | 0.966▲ | 1.348▲ |
| RSI | 50.313▲ | 64.369▲ | 66.043▲ | 71.232▲ | 67.210▲ |
| STOCH | 40.945 | 74.031 | 90.709▲ | 74.957 | 76.790 |
| WILL %R | -28.205 | -16.296▲ | -9.598▲ | -5.727▲ | -3.104▲ |
| CCI | -10.440 | 31.004 | 71.756 | 222.836▲ | 181.323▲ |
|
Saturday, October 10, 2026 12:11 AM
AbbVie (NYSE:ABBV) received two FDA Breakthrough Therapy Designations for its experimental cancer drug telisotuzumab adizutecan in colorectal and non small cell lung cancer. The designations apply to ...
|
|
Friday, October 09, 2026 07:00 AM
Humira, the drug that built AbbVie (NYSE:ABBV), sold $756 million last quarter, down 35.9%. And yet total revenue still climbed 10.2% to $16.99 billion. That’s what replacing a blockbuster looks like ...
|
|
Friday, October 09, 2026 05:20 AM
Cantor Fitzgerald analyst Carter Gould maintained a Buy rating on AbbVie today and set a price target of $290.00. According to TipRanks, Gould is a 4-star analyst with an average return of 6.4% and a ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 09/10/26 | 271.53 | 277.60 | 270.38 | 276.47 | 4,262,368 |
| 08/10/26 | 270.98 | 272.515 | 265.71 | 272.42 | 4,279,280 |
| 07/10/26 | 268.40 | 274.94 | 266.89 | 271.36 | 5,349,525 |
| 06/10/26 | 267.74 | 268.8582 | 260.6197 | 266.69 | 4,410,856 |
| 05/10/26 | 261.27 | 267.34 | 260.29 | 265.76 | 7,543,627 |
| 02/10/26 | 259.74 | 264.06 | 257.87 | 262.82 | 5,540,047 |
| 01/10/26 | 260.51 | 262.3158 | 259.00 | 259.93 | 3,826,213 |
| 30/09/26 | 264.60 | 265.36 | 261.59 | 261.59 | 4,261,099 |
| 29/09/26 | 265.45 | 268.93 | 261.5213 | 263.29 | 3,883,993 |
| 28/09/26 | 264.33 | 267.735 | 263.38 | 266.28 | 4,428,616 |
|
|
||||
|
|
||||
|
|